Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8594 |
High Similarity |
NPD1091 |
Approved |
0.8403 |
Intermediate Similarity |
NPD1653 |
Approved |
0.8357 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.8345 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.8309 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8309 |
Intermediate Similarity |
NPD1613 |
Approved |
0.8308 |
Intermediate Similarity |
NPD3705 |
Approved |
0.8222 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.8077 |
Intermediate Similarity |
NPD1357 |
Approved |
0.8015 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7941 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7848 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7812 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7808 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7799 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7799 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7778 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7769 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7763 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7734 |
Intermediate Similarity |
NPD228 |
Approved |
0.7681 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7673 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7654 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.764 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7622 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7622 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7622 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7615 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7603 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7593 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7586 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7582 |
Intermediate Similarity |
NPD37 |
Approved |
0.758 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7569 |
Intermediate Similarity |
NPD5960 |
Phase 3 |
0.7569 |
Intermediate Similarity |
NPD5588 |
Approved |
0.7562 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7559 |
Intermediate Similarity |
NPD290 |
Approved |
0.7548 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7548 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7548 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7546 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7518 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7518 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7517 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7464 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7452 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7445 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.744 |
Intermediate Similarity |
NPD291 |
Approved |
0.7429 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7379 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.7378 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7376 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7375 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7372 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7365 |
Intermediate Similarity |
NPD4236 |
Phase 3 |
0.7365 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.7365 |
Intermediate Similarity |
NPD4237 |
Approved |
0.7355 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7353 |
Intermediate Similarity |
NPD5846 |
Approved |
0.7353 |
Intermediate Similarity |
NPD6516 |
Phase 2 |
0.7343 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7343 |
Intermediate Similarity |
NPD1726 |
Clinical (unspecified phase) |
0.7333 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7329 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7329 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7329 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7325 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.732 |
Intermediate Similarity |
NPD3686 |
Approved |
0.732 |
Intermediate Similarity |
NPD3687 |
Approved |
0.7308 |
Intermediate Similarity |
NPD2977 |
Approved |
0.7308 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7308 |
Intermediate Similarity |
NPD556 |
Approved |
0.7292 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7292 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7292 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7285 |
Intermediate Similarity |
NPD1774 |
Approved |
0.7273 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7273 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7267 |
Intermediate Similarity |
NPD2677 |
Approved |
0.7266 |
Intermediate Similarity |
NPD3685 |
Discontinued |
0.7266 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7261 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7255 |
Intermediate Similarity |
NPD2122 |
Discontinued |
0.7248 |
Intermediate Similarity |
NPD4162 |
Approved |
0.7241 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7239 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7226 |
Intermediate Similarity |
NPD5126 |
Approved |
0.7226 |
Intermediate Similarity |
NPD5125 |
Phase 3 |
0.7211 |
Intermediate Similarity |
NPD4108 |
Discontinued |
0.7205 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7203 |
Intermediate Similarity |
NPD7095 |
Approved |
0.72 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.72 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7197 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7197 |
Intermediate Similarity |
NPD5772 |
Approved |
0.7197 |
Intermediate Similarity |
NPD5773 |
Approved |
0.7195 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7194 |
Intermediate Similarity |
NPD2235 |
Phase 2 |
0.7194 |
Intermediate Similarity |
NPD2231 |
Phase 2 |
0.7192 |
Intermediate Similarity |
NPD6653 |
Approved |
0.7172 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.717 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7169 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7153 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7153 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7152 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7143 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7133 |
Intermediate Similarity |
NPD5752 |
Clinical (unspecified phase) |
0.7133 |
Intermediate Similarity |
NPD3060 |
Approved |
0.7132 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7124 |
Intermediate Similarity |
NPD4123 |
Phase 3 |
0.7123 |
Intermediate Similarity |
NPD4340 |
Discontinued |
0.7118 |
Intermediate Similarity |
NPD6843 |
Phase 3 |
0.7118 |
Intermediate Similarity |
NPD6842 |
Approved |
0.7118 |
Intermediate Similarity |
NPD6841 |
Approved |
0.7114 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7114 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7105 |
Intermediate Similarity |
NPD6783 |
Clinical (unspecified phase) |
0.7095 |
Intermediate Similarity |
NPD6029 |
Clinical (unspecified phase) |
0.7095 |
Intermediate Similarity |
NPD6028 |
Clinical (unspecified phase) |
0.7089 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7086 |
Intermediate Similarity |
NPD6331 |
Phase 2 |
0.7086 |
Intermediate Similarity |
NPD4535 |
Phase 3 |
0.7086 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7083 |
Intermediate Similarity |
NPD3179 |
Approved |
0.7083 |
Intermediate Similarity |
NPD3180 |
Approved |
0.7078 |
Intermediate Similarity |
NPD7526 |
Approved |
0.7078 |
Intermediate Similarity |
NPD7527 |
Clinical (unspecified phase) |
0.7078 |
Intermediate Similarity |
NPD52 |
Approved |
0.7077 |
Intermediate Similarity |
NPD968 |
Approved |
0.7067 |
Intermediate Similarity |
NPD2424 |
Discontinued |
0.7055 |
Intermediate Similarity |
NPD4140 |
Approved |
0.705 |
Intermediate Similarity |
NPD3496 |
Discontinued |
0.7047 |
Intermediate Similarity |
NPD2161 |
Phase 2 |
0.7044 |
Intermediate Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.7037 |
Intermediate Similarity |
NPD8127 |
Discontinued |
0.7034 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.702 |
Intermediate Similarity |
NPD5177 |
Phase 3 |
0.7015 |
Intermediate Similarity |
NPD821 |
Approved |
0.7015 |
Intermediate Similarity |
NPD5535 |
Approved |
0.7007 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7007 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7007 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7006 |
Intermediate Similarity |
NPD4675 |
Approved |
0.7006 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7006 |
Intermediate Similarity |
NPD4678 |
Approved |
0.7 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.6993 |
Remote Similarity |
NPD6584 |
Phase 3 |
0.6993 |
Remote Similarity |
NPD558 |
Phase 2 |
0.6988 |
Remote Similarity |
NPD5844 |
Phase 1 |
0.6986 |
Remote Similarity |
NPD4062 |
Phase 3 |
0.6982 |
Remote Similarity |
NPD8312 |
Approved |
0.6982 |
Remote Similarity |
NPD8313 |
Approved |
0.6978 |
Remote Similarity |
NPD1778 |
Approved |
0.6968 |
Remote Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.6966 |
Remote Similarity |
NPD4625 |
Phase 3 |
0.6948 |
Remote Similarity |
NPD1511 |
Approved |
0.6943 |
Remote Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.6939 |
Remote Similarity |
NPD5837 |
Clinical (unspecified phase) |
0.6937 |
Remote Similarity |
NPD2563 |
Approved |
0.6937 |
Remote Similarity |
NPD2560 |
Approved |
0.6928 |
Remote Similarity |
NPD3751 |
Discontinued |
0.6928 |
Remote Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.6918 |
Remote Similarity |
NPD7945 |
Clinical (unspecified phase) |
0.6917 |
Remote Similarity |
NPD3022 |
Approved |
0.6917 |
Remote Similarity |
NPD3021 |
Approved |
0.6903 |
Remote Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.6903 |
Remote Similarity |
NPD4739 |
Approved |
0.6901 |
Remote Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.6901 |
Remote Similarity |
NPD5327 |
Phase 3 |
0.6899 |
Remote Similarity |
NPD4380 |
Phase 2 |
0.6894 |
Remote Similarity |
NPD1358 |
Approved |
0.6894 |
Remote Similarity |
NPD3882 |
Suspended |
0.6892 |
Remote Similarity |
NPD1933 |
Approved |
0.689 |
Remote Similarity |
NPD6071 |
Discontinued |
0.689 |
Remote Similarity |
NPD3051 |
Approved |
0.6887 |
Remote Similarity |
NPD3540 |
Phase 1 |
0.6879 |
Remote Similarity |
NPD422 |
Phase 1 |
0.6875 |
Remote Similarity |
NPD1465 |
Phase 2 |
0.6875 |
Remote Similarity |
NPD6818 |
Clinical (unspecified phase) |
0.6871 |
Remote Similarity |
NPD2674 |
Phase 3 |
0.6871 |
Remote Similarity |
NPD5494 |
Approved |
0.6867 |
Remote Similarity |
NPD7033 |
Discontinued |
0.6863 |
Remote Similarity |
NPD6658 |
Clinical (unspecified phase) |
0.6859 |
Remote Similarity |
NPD1512 |
Approved |
0.6855 |
Remote Similarity |
NPD4773 |
Phase 2 |
0.6855 |
Remote Similarity |
NPD9365 |
Approved |
0.6855 |
Remote Similarity |
NPD4772 |
Phase 2 |
0.6852 |
Remote Similarity |
NPD5604 |
Discontinued |
0.6848 |
Remote Similarity |
NPD2970 |
Approved |
0.6848 |
Remote Similarity |
NPD2969 |
Approved |
0.6846 |
Remote Similarity |
NPD2492 |
Phase 1 |
0.6842 |
Remote Similarity |
NPD7153 |
Discontinued |
0.6835 |
Remote Similarity |
NPD3866 |
Clinical (unspecified phase) |
0.6835 |
Remote Similarity |
NPD1894 |
Discontinued |
0.6835 |
Remote Similarity |
NPD4005 |
Discontinued |
0.6835 |
Remote Similarity |
NPD1182 |
Approved |
0.6832
|
Remote Similarity |
NPD5402 |
Approved |